货号:GS40717
Tifcemalimab (TAB004/JS004) is a humanized IgG4 kappa monoclonal antibody targeting B- and T-lymphocyte attenuator (BTLA), an inhibitory immune checkpoint receptor expressed on T cells, B cells, and dendritic cells. It binds to BTLA to block its interaction with the ligand herpesvirus entry mediator (HVEM), thereby reversing immune suppression and enhancing anti-tumor immunity. It is being developed for cancer immunotherapy, often in combination with PD-1 inhibitors, for the treatment of advanced solid tumors.
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
迈思生物